AP2014008139A0 - Acrylamide compounds as histamine H3 receptor ligands - Google Patents
Acrylamide compounds as histamine H3 receptor ligandsInfo
- Publication number
- AP2014008139A0 AP2014008139A0 AP2014008139A AP2014008139A AP2014008139A0 AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0 AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0
- Authority
- AP
- ARIPO
- Prior art keywords
- histamine
- receptor ligands
- acrylamide compounds
- acrylamide
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3464CH2012 | 2012-08-23 | ||
PCT/IN2012/000796 WO2014030170A1 (fr) | 2012-08-23 | 2012-12-05 | Composés acrylamides utilisés comme ligands des récepteurs h3 à l'histamine |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2014008139A0 true AP2014008139A0 (en) | 2014-12-31 |
Family
ID=54187093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2014008139A AP2014008139A0 (en) | 2012-08-23 | 2012-12-05 | Acrylamide compounds as histamine H3 receptor ligands |
Country Status (27)
Country | Link |
---|---|
US (1) | US9328092B2 (fr) |
EP (1) | EP2888243B1 (fr) |
JP (1) | JP5981654B2 (fr) |
KR (1) | KR101707343B1 (fr) |
CN (1) | CN104540812B (fr) |
AP (1) | AP2014008139A0 (fr) |
AU (1) | AU2012388383C1 (fr) |
BR (1) | BR112015001524B1 (fr) |
CA (1) | CA2878217C (fr) |
CY (1) | CY1118035T1 (fr) |
DK (1) | DK2888243T3 (fr) |
EA (1) | EA025136B1 (fr) |
ES (1) | ES2592819T3 (fr) |
HK (1) | HK1204620A1 (fr) |
HR (1) | HRP20161167T1 (fr) |
HU (1) | HUE030901T2 (fr) |
IL (1) | IL236437A (fr) |
LT (1) | LT2888243T (fr) |
ME (1) | ME02519B (fr) |
MX (1) | MX360001B (fr) |
PL (1) | PL2888243T3 (fr) |
PT (1) | PT2888243T (fr) |
RS (1) | RS55158B1 (fr) |
SG (1) | SG11201408423XA (fr) |
SI (1) | SI2888243T1 (fr) |
SM (1) | SMT201600336B (fr) |
WO (1) | WO2014030170A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11313246B2 (en) * | 2016-11-30 | 2022-04-26 | General Electric Company | Gas turbine engine wash system |
WO2022113008A1 (fr) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique |
WO2023166351A1 (fr) * | 2022-03-02 | 2023-09-07 | 杭州百诚医药科技股份有限公司 | Antagoniste du récepteur h3 de l'histamine et son utilisation médicale |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2526518A1 (fr) * | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Derives de 1-aryl-4-(aryloxycarbonyl)-piperazine utilises en tant qu'inhibiteurs de la lipase hormonosensible |
US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
ES2299074T3 (es) | 2004-06-02 | 2008-05-16 | F. Hoffmann-La Roche Ag | Derivados de naftaleno utiles como ligandos del receptor 3 de la histamina. |
WO2005123716A1 (fr) * | 2004-06-21 | 2005-12-29 | F. Hoffmann-La Roche Ag | Derives d'indole utilises comme antagonistes du recepteur de l'histamine |
BRPI0514553A (pt) | 2004-08-23 | 2008-06-17 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo |
AU2006319232B2 (en) * | 2005-11-30 | 2012-09-13 | F. Hoffmann-La Roche Ag | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators |
JP2009538859A (ja) | 2006-05-30 | 2009-11-12 | エフ.ホフマン−ラ ロシュ アーゲー | ピペリジニルピリミジン誘導体 |
BRPI0814532A2 (pt) * | 2007-07-25 | 2015-01-27 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos. |
CL2008002622A1 (es) | 2007-09-06 | 2009-11-27 | Glaxo Group Ltd | 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno. |
WO2009100120A2 (fr) | 2008-02-04 | 2009-08-13 | Neurogen Corporation | Pipérazinyl-oxoéthyl-tétrahydropyrazolopyridines substituées par du pyridinyle |
CA2719985A1 (fr) | 2008-03-31 | 2009-10-08 | Evotec Ag | Tetrahydronaphthyridines et ses derives aza a titre d'antagonistes des recepteurs d'histamine h3 |
WO2009135842A1 (fr) | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azétidines et cyclobutanes comme antagonistes des récepteurs h3 de l’histamine |
CA2812970C (fr) * | 2010-09-02 | 2015-01-13 | Suven Life Sciences Limited | Composes heterocyclyle comme ligands des recepteurs h3 de l'histamine |
-
2012
- 2012-12-05 KR KR1020157001952A patent/KR101707343B1/ko active IP Right Grant
- 2012-12-05 AU AU2012388383A patent/AU2012388383C1/en active Active
- 2012-12-05 JP JP2015528009A patent/JP5981654B2/ja active Active
- 2012-12-05 AP AP2014008139A patent/AP2014008139A0/xx unknown
- 2012-12-05 HU HUE12844650A patent/HUE030901T2/en unknown
- 2012-12-05 PL PL12844650T patent/PL2888243T3/pl unknown
- 2012-12-05 DK DK12844650.7T patent/DK2888243T3/en active
- 2012-12-05 BR BR112015001524-7A patent/BR112015001524B1/pt active IP Right Grant
- 2012-12-05 EA EA201590413A patent/EA025136B1/ru unknown
- 2012-12-05 SG SG11201408423XA patent/SG11201408423XA/en unknown
- 2012-12-05 LT LTEP12844650.7T patent/LT2888243T/lt unknown
- 2012-12-05 MX MX2015000064A patent/MX360001B/es active IP Right Grant
- 2012-12-05 CA CA2878217A patent/CA2878217C/fr active Active
- 2012-12-05 PT PT128446507T patent/PT2888243T/pt unknown
- 2012-12-05 WO PCT/IN2012/000796 patent/WO2014030170A1/fr active Application Filing
- 2012-12-05 US US14/419,474 patent/US9328092B2/en active Active
- 2012-12-05 ME MEP-2016-190A patent/ME02519B/fr unknown
- 2012-12-05 RS RS20160783A patent/RS55158B1/sr unknown
- 2012-12-05 EP EP12844650.7A patent/EP2888243B1/fr active Active
- 2012-12-05 SI SI201230707A patent/SI2888243T1/sl unknown
- 2012-12-05 CN CN201280075253.4A patent/CN104540812B/zh active Active
- 2012-12-05 ES ES12844650.7T patent/ES2592819T3/es active Active
-
2014
- 2014-12-24 IL IL236437A patent/IL236437A/en active IP Right Grant
-
2015
- 2015-06-02 HK HK15105257.0A patent/HK1204620A1/xx unknown
-
2016
- 2016-09-13 HR HRP20161167TT patent/HRP20161167T1/hr unknown
- 2016-09-22 CY CY20161100943T patent/CY1118035T1/el unknown
- 2016-09-23 SM SM201600336T patent/SMT201600336B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
EP2925129A4 (fr) | Composés pro-neurogènes | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2887803A4 (fr) | Composés pro-neurogéniques | |
AP2015008591A0 (en) | Heterocyclic compounds | |
EP2828262A4 (fr) | Composés d'imidazotriazinone | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
HK1187613A1 (en) | Compounds as histamine h3 receptor ligands h3 | |
GB201209096D0 (en) | Compounds | |
HK1204620A1 (en) | Acrylamide compounds as histamine h3 receptor ligands h3 | |
HK1180955A1 (en) | Heterocyclyl compounds as histamine h3 receptor ligands h3 | |
GB201217310D0 (en) | Compounds | |
ZA201409244B (en) | Acrylamide compounds as histamine h3 receptor ligands | |
TH1501000921A (th) | สารประกอบอะคริลาไมด์ในฐานะลิแกนด์ของฮิสตะมีน h3 รีเซปเตอร์ | |
GB201211308D0 (en) | Compounds for use | |
GB201211086D0 (en) | Novel anti-cancer compounds | |
GB201217311D0 (en) | Compounds | |
GB201217290D0 (en) | Compounds | |
GB201217312D0 (en) | Compounds | |
GB201215284D0 (en) | Compounds | |
TH1401001203B (th) | สารประกอบเฮเทอโรเอริลในฐานะที่เป็น 5-ht4 รีเซปเตอร์ลิแกนด์ | |
GB201214250D0 (en) | Compounds |